JPWO2024262491A5 - - Google Patents

Info

Publication number
JPWO2024262491A5
JPWO2024262491A5 JP2025528066A JP2025528066A JPWO2024262491A5 JP WO2024262491 A5 JPWO2024262491 A5 JP WO2024262491A5 JP 2025528066 A JP2025528066 A JP 2025528066A JP 2025528066 A JP2025528066 A JP 2025528066A JP WO2024262491 A5 JPWO2024262491 A5 JP WO2024262491A5
Authority
JP
Japan
Prior art keywords
crystal
hydrate
values
diffraction
diffraction angles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2025528066A
Other languages
English (en)
Japanese (ja)
Other versions
JP7904995B2 (ja
JPWO2024262491A1 (cg-RX-API-DMAC7.html
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2024/022040 external-priority patent/WO2024262491A1/ja
Publication of JPWO2024262491A1 publication Critical patent/JPWO2024262491A1/ja
Publication of JPWO2024262491A5 publication Critical patent/JPWO2024262491A5/ja
Application granted granted Critical
Publication of JP7904995B2 publication Critical patent/JP7904995B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2025528066A 2023-06-19 2024-06-18 Nrf2活性化作用を有する含窒素複素環化合物の結晶 Active JP7904995B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2023100075 2023-06-19
JP2023100075 2023-06-19
PCT/JP2024/022040 WO2024262491A1 (ja) 2023-06-19 2024-06-18 Nrf2活性化作用を有する含窒素複素環化合物の結晶

Publications (3)

Publication Number Publication Date
JPWO2024262491A1 JPWO2024262491A1 (cg-RX-API-DMAC7.html) 2024-12-26
JPWO2024262491A5 true JPWO2024262491A5 (cg-RX-API-DMAC7.html) 2026-06-11
JP7904995B2 JP7904995B2 (ja) 2026-08-13

Family

ID=93935419

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025528066A Active JP7904995B2 (ja) 2023-06-19 2024-06-18 Nrf2活性化作用を有する含窒素複素環化合物の結晶

Country Status (9)

Country Link
EP (1) EP4696692A1 (cg-RX-API-DMAC7.html)
JP (1) JP7904995B2 (cg-RX-API-DMAC7.html)
KR (1) KR20260023529A (cg-RX-API-DMAC7.html)
CN (1) CN121152792A (cg-RX-API-DMAC7.html)
AU (1) AU2024314540A1 (cg-RX-API-DMAC7.html)
IL (1) IL324833A (cg-RX-API-DMAC7.html)
MX (1) MX2025014082A (cg-RX-API-DMAC7.html)
TW (1) TW202504613A (cg-RX-API-DMAC7.html)
WO (1) WO2024262491A1 (cg-RX-API-DMAC7.html)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
TWI649330B (zh) 2013-04-24 2019-02-01 艾伯維有限公司 甲基巴多索龍之2,2-二氟丙醯胺衍生物、其多晶形及其使用方法
US20190380992A1 (en) 2014-12-04 2019-12-19 Biogen Ma Inc. Multiple Sclerosis Treatment Regimen Using Dimethyl Fumarate
JP2020097526A (ja) * 2017-03-28 2020-06-25 武田薬品工業株式会社 複素環化合物
JOP20210030A1 (ar) 2018-08-20 2021-02-16 Janssen Pharmaceutica Nv مثبطات تفاعل البروتين-بروتين KEAP1-Nrf2
KR102932313B1 (ko) 2019-02-15 2026-02-26 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Nrf2 활성화제로서 히드록시피리드옥사제핀
CN114174289B (zh) 2019-05-31 2025-03-07 Ube株式会社 苯并三唑衍生物
GB202005852D0 (en) 2020-04-22 2020-06-03 C4X Discovery Ltd Therapeutic compounds
CN114507181B (zh) 2020-11-17 2024-03-26 中国医学科学院药物研究所 含5-取代四氢异喹啉的丙酸类化合物、其药物组合物和应用
CR20240325A (es) 2022-01-07 2024-11-22 Chugai Pharmaceutical Co Ltd Compuesto heterocíclico que contiene nitrógeno que tiene un efecto de activación del nrf2